Literature DB >> 31402950

Establishment of an insufficient radiofrequency ablation orthotopic nude mouse model of hepatocellular carcinoma to study the invasiveness and metastatic potential of residual cancer.

Ning Zhang1, Hua Zhu2, Ye-Hao Dong3, Lu Wang1.   

Abstract

In order to assess the metastatic potential of residual hepatocellular carcinoma (HCC) following insufficient radiofrequency ablation (RFA) and to improve the current animal model, an insufficient RFA orthotopic nude mouse model of HCC was developed in the present study. A human HCC orthotopic nude mouse model was established using HCCLM3 cells, which has a high metastatic potential, labeled with green fluorescent protein. A total of 12 nude mice within the RFA group received insufficient RFA and 12 mice in the control group received RFA needle electrode puncture of the tumor without ablation, 3 weeks after implantation. To investigate tumor growth and metastasis, 4 weeks after RFA, six mice in each group were sacrificed and the remaining mice in each group were maintained until death to evaluate their life span. No mice died following insufficient RFA and the success rate was 100%. Compared with the control group, the intrahepatic and lung metastasis rates were higher in the RFA group, despite the mice having smaller tumor volumes and longer survival times. Lung and intrahepatic metastasis rates in the insufficient RFA group were 100% (6/6) and 66.67% (4/6), respectively, compared with 33.33% (2/6) and 0% (0/6), respectively, in the control group. As part of the study, a safe and reliable method to establish an insufficient RFA orthotopic nude mouse model was developed. The present study revealed that residual cancer following insufficient RFA had exhibited increased invasiveness and metastatic potential.

Entities:  

Keywords:  hepatocellular carcinoma; insufficient radiofrequency ablation; nude mouse; orthotopic transplantation tumor; residual cancer

Year:  2019        PMID: 31402950      PMCID: PMC6676705          DOI: 10.3892/ol.2019.10552

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

Review 1.  The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review.

Authors:  Wan Yee Lau; Eric C H Lai
Journal:  Ann Surg       Date:  2009-01       Impact factor: 12.969

2.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

Authors:  Kai Feng; Jun Yan; Xiaowu Li; Feng Xia; Kuansheng Ma; Shuguang Wang; Ping Bie; Jiahong Dong
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

3.  High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential.

Authors:  L Wang; Z Y Tang; L X Qin; X F Wu; H C Sun; Q Xue; S L Ye
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

4.  Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma.

Authors:  Shan Ke; Xue-mei Ding; Jian Kong; Jun Gao; Shao-hong Wang; Yan Cheng; Wen-bing Sun
Journal:  J Transl Med       Date:  2010-07-29       Impact factor: 5.531

5.  Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice.

Authors:  Bi-Wei Yang; Ying Liang; Jing-Lin Xia; Hui-Chuan Sun; Lu Wang; Ju-Bo Zhang; Zhao-You Tang; Kang-Da Liu; Jie Chen; Qiong Xue; Jun Chen; Dong-Mei Gao; Wei-Zhong Wu
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 2.566

6.  Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors.

Authors:  Vincent Wai-To Lam; Kelvin K Ng; Kenneth Siu-Ho Chok; Tan-To Cheung; Jimmy Yuen; Helen Tung; Wai-Kuen Tso; Sheung-Tat Fan; Ronnie T P Poon
Journal:  Ann Surg Oncol       Date:  2007-12-20       Impact factor: 5.344

7.  Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients.

Authors:  Masahiko Koda; Yoshikazu Murawaki; Yasuaki Hirooka; Mikiya Kitamoto; Masafumi Ono; Hiroshi Sakaeda; Kouji Joko; Shuichi Sato; Katsuyoshi Tamaki; Takahiro Yamasaki; Hiroshi Shibata; Toshinari Shimoe; Tadakazu Matsuda; Nobuyuki Toshikuni; Shin-Ichi Fujioka; Kenji Ohmoto; Shinichiro Nakamura; Kazuya Kariyama; Hiroshi Aikata; Yoshiyuki Kobayashi; Akemi Tsutsui
Journal:  Hepatol Res       Date:  2012-05-14       Impact factor: 4.288

8.  Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients.

Authors:  Hiroshi Kasugai; Yukio Osaki; Hiroko Oka; Masatoshi Kudo; Toshihito Seki
Journal:  Oncology       Date:  2007-12-13       Impact factor: 2.935

9.  Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

Authors:  Shuichiro Shiina; Ryosuke Tateishi; Toru Arano; Koji Uchino; Kenichiro Enooku; Hayato Nakagawa; Yoshinari Asaoka; Takahisa Sato; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  Am J Gastroenterol       Date:  2011-12-13       Impact factor: 10.864

10.  Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.

Authors:  Jian Kong; Jinge Kong; Bing Pan; Shan Ke; Shuying Dong; Xiuli Li; Aimin Zhou; Lemin Zheng; Wen-bing Sun
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

View more
  3 in total

Review 1.  Platelets for cancer treatment and drug delivery.

Authors:  Gaozhe Xiao; Zhikun Zhang; Qiaoying Chen; Tao Wu; Wei Shi; Lu Gan; Xiuli Liu; Yong Huang; Mengyu Lv; Yongxiang Zhao; Pan Wu; Liping Zhong; Jian He
Journal:  Clin Transl Oncol       Date:  2022-02-26       Impact factor: 3.405

2.  Specific Inhibitor of Matrix Metalloproteinase Decreases Tumor Invasiveness After Radiofrequency Ablation in Liver Tumor Animal Model.

Authors:  An-Na Jiang; Jing-Tao Liu; Kun Zhao; Hao Wu; Song Wang; Kun Yan; Wei Yang
Journal:  Front Oncol       Date:  2020-11-18       Impact factor: 6.244

3.  Incomplete thermal ablation-induced up-regulation of transcription factor nuclear receptor subfamily 2, group F, member 6 (NR2F6) contributes to the rapid progression of residual liver tumor in hepatoblastoma.

Authors:  Jin-Shu Pang; Dong-Yue Wen; Rong-Quan He; Gang Chen; Peng Lin; Jin-Hong Li; Yu-Jia Zhao; Lin-Yong Wu; Jun-Hong Chen; Yun He; Li-Ting Qin; Jia-Bo Chen; Yong Li; Hong Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.